FGFR inhibitors in urothelial cancer: Contextualizing THOR within the new treatment landscape

Kriti Mittal; Monika Joshi

doi:10.1016/j.medj.2023.12.008

FGFR inhibitors in urothelial cancer: Contextualizing THOR within the new treatment landscape

Kriti Mittal
, Monika Joshi

Research output: Contribution to journal › Comment/debate › peer-review

Abstract

As frontline treatment of advanced urothelial cancer (UC) evolves, optimal sequencing of subsequent therapies remains unclear. The phase 3 THOR trial compared the efficacy of erdafitinib to chemotherapy or immunotherapy in FGFR3/2-altered advanced UC. THOR offers valuable data informing sequencing strategies, reinforcing the need for molecular testing in UC.

Original language	English (US)
Pages (from-to)	176-178
Number of pages	3
Journal	Med
Volume	5
Issue number	3
DOIs	https://doi.org/10.1016/j.medj.2023.12.008
State	Published - Mar 8 2024

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

All Science Journal Classification (ASJC) codes

General Medicine

Access to Document

10.1016/j.medj.2023.12.008

Cite this

@article{31e1cfc3eacd45b2bface8c7e820ac31,

title = "FGFR inhibitors in urothelial cancer: Contextualizing THOR within the new treatment landscape",

abstract = "As frontline treatment of advanced urothelial cancer (UC) evolves, optimal sequencing of subsequent therapies remains unclear. The phase 3 THOR trial compared the efficacy of erdafitinib to chemotherapy or immunotherapy in FGFR3/2-altered advanced UC. THOR offers valuable data informing sequencing strategies, reinforcing the need for molecular testing in UC.",

author = "Kriti Mittal and Monika Joshi",

note = "Publisher Copyright: {\textcopyright} 2023 Elsevier Inc.",

year = "2024",

month = mar,

day = "8",

doi = "10.1016/j.medj.2023.12.008",

language = "English (US)",

volume = "5",

pages = "176--178",

journal = "Med",

issn = "2666-6359",

publisher = "Cell Press",

number = "3",

}

TY - JOUR

T1 - FGFR inhibitors in urothelial cancer

T2 - Contextualizing THOR within the new treatment landscape

AU - Mittal, Kriti

AU - Joshi, Monika

PY - 2024/3/8

Y1 - 2024/3/8

N2 - As frontline treatment of advanced urothelial cancer (UC) evolves, optimal sequencing of subsequent therapies remains unclear. The phase 3 THOR trial compared the efficacy of erdafitinib to chemotherapy or immunotherapy in FGFR3/2-altered advanced UC. THOR offers valuable data informing sequencing strategies, reinforcing the need for molecular testing in UC.

AB - As frontline treatment of advanced urothelial cancer (UC) evolves, optimal sequencing of subsequent therapies remains unclear. The phase 3 THOR trial compared the efficacy of erdafitinib to chemotherapy or immunotherapy in FGFR3/2-altered advanced UC. THOR offers valuable data informing sequencing strategies, reinforcing the need for molecular testing in UC.

UR - https://www.scopus.com/pages/publications/85186687206

UR - https://www.scopus.com/pages/publications/85186687206#tab=citedBy

U2 - 10.1016/j.medj.2023.12.008

DO - 10.1016/j.medj.2023.12.008

M3 - Comment/debate

C2 - 38460495

AN - SCOPUS:85186687206

SN - 2666-6359

VL - 5

SP - 176

EP - 178

JO - Med

JF - Med

IS - 3

ER -

FGFR inhibitors in urothelial cancer: Contextualizing THOR within the new treatment landscape

Abstract

UN SDGs

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this